| |
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now.
|
|
Today’s Big NewsJul 22, 2024 |
| By Nick Paul Taylor Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent and is delaying the use of Regeneron and Sanofi’s blockbuster. |
|
|
|
By Zoey Becker While President Joe Biden is officially out for the 2024 election, his term has certainly made a mark in the healthcare realm. |
By Annalee Armstrong A doomed merger sent Infinity pharma filing for bankruptcy last year. Now, the other half of that ill-fated deal is facing its end as well. |
By Conor Hale Intelligent Ultrasound’s ScanNav software has already helped bolster GE HealthCare’s scanners, through the latter's SonoLyst image recognition programs. |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
By Angus Liu While the international IT outage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced cancelations at hospitals, the experience from the meltdown appeared different at large pharma companies. |
By Nick Paul Taylor Innovent has pulled off another late-phase win for its Eli Lilly-partnered GLP-1 drug candidate, linking the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China. |
By Annalee Armstrong Allarity Therapeutics has received notice from the Securities and Exchange Commission that an enforcement action is pending regarding FDA meetings surrounding the new drug application for cancer therapy dovitinib. |
By Fraiser Kansteiner Agilent has revealed that it’s signed a definitive agreement to acquire Biovectra for $925 million through a mix of cash and debt financing. The deal is expected to close this year. |
By Angus Liu When pharma companies launch marketing campaigns, they typically seek to spotlight positive factors about their medicines. But in a special case, CSL Vifor will need to use its commercialization prowess to resolve an antitrust case in Europe. |
By Andrea Park There’s a new contender for song of the summer out now, and it comes from none other than diabetes tech maker Insulet. |
By James Waldron Actuate Therapeutics was already keeping its planned IPO on the modest side, but the cancer-focused biotech has now lowered those expectations even further. |
By Conor Hale Tulavi Therapeutics' de novo clearance covers an absorbable hydrogel that encases the end of a severed nerve, preventing it from trying to regenerate. |
Fierce podcastsDon’t miss an episode |
| | In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
